<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776059</url>
  </required_header>
  <id_info>
    <org_study_id>SCAH Consortium- AH Treatment</org_study_id>
    <secondary_id>5U01AA021886</secondary_id>
    <nct_id>NCT02776059</nct_id>
  </id_info>
  <brief_title>Pegfilgrastim in Patients With Alcoholic Hepatitis</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy Morgan, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, randomized trial of standard of care vs. standard of&#xD;
      care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic&#xD;
      hepatitis and DF≥32.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard of care treatment will be with either prednisolone 40 mg/day for 28 days or&#xD;
      pentoxifylline 400 mg TID for 28 days. The patient's physician will decide the standard of&#xD;
      care treatment the patient will receive. Patients will be randomized (1:1) to receive either&#xD;
      no additional drug treatment (SOC group) or to receive a pegfilgrastim (Neulasta®, 6 mg) SQ.&#xD;
&#xD;
      Patients will be seen in-person at screening, randomization (Day 1), Day 8, Day 29, Week 12,&#xD;
      and Week 24. Safety examination and blood tests will be performed. In addition, biological&#xD;
      specimens will be saved for research purposes at these time points.&#xD;
&#xD;
      Total duration of patient participation is 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2017</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, especially infection and renal failure, Change in MELD Score and DF between Day 1 and Day 29, Lille score (at Day 8)</measure>
    <time_frame>Day 1, Day 8, Day 29, and Day 90</time_frame>
    <description>The primary outcome will be survival at Day 90. Assuming a fixed sample size of 70 patients (35 per arm), a one-sided z-test will have 81.6% power to detect a 25% improvement in survival proportions between arms, with survival in the standard of care arm at 65%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>adverse events through Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>Day 29</time_frame>
    <description>Change in MELD and Maddrey DF during first 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>Day 8</time_frame>
    <description>Change in Lille score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>at Day 90</time_frame>
    <description>survival at Day 90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>prednisolone or pentoxifylline + pegfiltrastim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prednisolone or pentoxifylline for 28 days PO plus pegfilgrastim subcutaneous weekly shot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisolone or pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prednisolone or pentoxifylline for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care + pegfiltrastim</intervention_name>
    <description>prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ</description>
    <arm_group_label>prednisolone or pentoxifylline + pegfiltrastim</arm_group_label>
    <other_name>Neulasta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Oral prednisolone or pentoxifyline for 28 days only</description>
    <arm_group_label>prednisolone or pentoxifylline</arm_group_label>
    <other_name>prednisolone or pentoxifyline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis of alcoholic hepatitis with Maddrey's discriminant function score&#xD;
             ≥32. Age 18 years or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal failure (creatinine &gt;2.0 mg/dl)&#xD;
&#xD;
          -  Bilirubin &lt;5 mg/dL&#xD;
&#xD;
          -  uncontrolled recent upper gastrointestinal bleeding&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Uncontrolled infection, or pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Morgan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>VA Long Beach Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>98022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico VA Health Care System</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Timothy Morgan, MD</investigator_full_name>
    <investigator_title>Chief of Hepatology</investigator_title>
  </responsible_party>
  <keyword>survival</keyword>
  <keyword>pegfilgrastim</keyword>
  <keyword>cirrhosis, alcoholic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patients' coded data will be shared .</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

